GeoVax Labs Expands HIV/AIDS Vaccine Program

GeoVax Labs Inc. announced the expansion of its preventative HIV/AIDS vaccine development program in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the HIV Vaccine Trials Network (HVTN), according to a GeoVax statement.

HVTN plans to clinically test the vaccine, which consists of a recombinant DNA vaccine that co-expresses human granulocyte-macrophage colony stimulating factor (GM-CSF) and non-infectious HIV virus-like particles. This builds on the DNA/MVA vaccine that’s currently in Phase 2a clinical testing through HVTN. The GM-CSF–enhanced vaccine has shown to protect against infection 70 percent of the time in non-human primates.

To read the GeoVax statement, visit: http://www.prweb.com/releases/2011/4/prweb8294136.htm.

The Friends of AIDS Foundation is dedicated to enhancing the quality of life for HIV positive individuals and empowering people to make healthy choices to prevent the spread of the HIV virus. To learn more about The Friends of AIDS Foundation, please visit: http://www.friendsofaids.org.


TOGETHER WE REMAIN STRONG!